Pharmaceutical Technology Europe, Sep 1, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Pharmaceutical Technology Europe, Sep 1, 2012
Special Feature
Strategies for High Containment
By Patricia Van Arnum
Experts share insight on facility design and operations for high-potency manufacturing.
Editor's Comment
European Commission Investigates Pay-to-Delay Deals
By Stephanie Sutton
Following an inquiry in 2009 that suggested the launch of various generic drugs was being delayed by anticompetitive business practices, the European Commission (EC) has been closely monitoring deals for potential breaches of the EU's antitrust rules.
Industry Insider
Regulatory Intervention in Paediatric Medicines
By Nathan Jessop
Regulators in both the EU and the US have attempted to stimulate paediatric-drug development with incentives offering extended periods of patent protection, but are these actions having the desired effects?
Outsoucing Review
The Macro View
By Jim Miller
The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Ask the Expert
Tackling Tablet Sticking
Rob Blanchard and Clive Roberts discuss the issues surrounding tablet sticking.
Disposables Advisor
Pre-use Filter-Integrity Testing: To Test or Not To Test?
By Jerold Martin
There is no harmonized guidance on pre-use integrity testing of sterilizing filters, prompting discussion among users as to whether such testing is necessary.
News
News
By Stephanie Sutton
Big Pharma Placed in Malpractice Spotlight and other news from across the globe.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here